eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed indications for presbyopia, myopia progression and mydriasis.

Presentation & Investor Materials

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News Releases
11/13/23
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
11/06/23
Eyenovia to Report Third Quarter 2023 Results on Monday, November 13
11/02/23
Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
Upcoming Events
There are currently no events scheduled.